GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » Net Current Asset Value

Conmed (Conmed) Net Current Asset Value

: $-27.63 (As of Dec. 2023)
View and export this data going back to 1987. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Conmed's net current asset value per share for the quarter that ended in Dec. 2023 was $-27.63.

The historical rank and industry rank for Conmed's Net Current Asset Value or its related term are showing as below:

CNMD's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.765
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Conmed Net Current Asset Value Historical Data

The historical data trend for Conmed's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.48 -21.67 -17.72 -31.84 -27.63

Conmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.84 -31.33 -30.16 -29.40 -27.63

Competitive Comparison

For the Medical Devices subindustry, Conmed's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed Price-to-Net-Current-Asset-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Conmed's Price-to-Net-Current-Asset-Value falls into.



Conmed Net Current Asset Value Calculation

Conmed's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(615.649-1465.799-0-0)/30.7652
=-27.63

Conmed's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(615.649-1465.799-0-0)/30.7652
=-27.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conmed  (NYSE:CNMD) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Conmed Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Conmed's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Conmed (Conmed) Business Description

Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Executives
Peters Stanley W Iii officer: VP GM General Surgery C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner officer: Executive Vice President & CFO C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford officer: VP Global Manufacturing C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell officer: Executive Vice President - HR C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon director HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Peter K Shagory officer: EVP,STRAT & CORP DEVT C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Daniel Jonas officer: Vice President/Legal Affairs, other: General Counsel C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge officer: VP Corp. Treasurer C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier officer: Treasurer and VP, Tax C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Jerome J. Lande director 1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007
Brent Lalomia officer: Vice President QA and RA C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John Jed Kennedy officer: VP GM GI C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Mark E Tryniski director C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773
Pat Beyer officer: President-Conmed International C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773